The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081754" target="_blank" >RIV/00023001:_____/21:00081754 - isvavai.cz</a>
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S2666776221001587?token=1619FCC667700FB687C82DF70C2316ECBC2ABDE36C3AAECFF032CAC903FB16E52074B771BF4B2F146C60C238B883ABD5&originRegion=eu-west-1&originCreation=20211201113839" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S2666776221001587?token=1619FCC667700FB687C82DF70C2316ECBC2ABDE36C3AAECFF032CAC903FB16E52074B771BF4B2F146C60C238B883ABD5&originRegion=eu-west-1&originCreation=20211201113839</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.lanepe.2021.100181" target="_blank" >10.1016/j.lanepe.2021.100181</a>
Alternative languages
Result language
angličtina
Original language name
The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey
Original language description
Background: Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for FMT in Europe. Methods: We invited all hospital-based FMT centres within the European Council member states to answer a web-based questionnaire covering their clinical activities, organisation, and regulation of FMT in 2019. Responders were identified from trials registered at clinicaltrials.gov and from the United European Gastroenterology (UEG) working group for stool banking and FMT. Findings: In 2019, 31 FMT centres from 17 countries reported a total of 1,874 (median 25, quartile 10.64) FMT procedures; 1,077 (57%) with Clostridioides difficile infection (CDI) as indication, 791 (42%) with experimental indications, and 6 (0.3%) unaccounted for. Adjusted to population size, 0.257 per 100,000 population received FMT for CDI and 0-189 per 100,000 population for experimental indications. With estimated 12,400 (6,100-8,500) annual cases of multiple, recurrent CDI and indication for FMT in Europe, the current European FMT activity covers approximately 10% of the patients with indication. The participating centres demonstrated high safety standards and adherence to international consensus guidelines. Formal or informal regulation from health authorities was present at 21 (68%) centres. Interpretation: FMT is a widespread routine treatment for multiple, recurrent CDI and an experimental treatment. Embedded within hospital settings, FMT centres operate with high standards across Europe to provide safe FMT. A significant gap in FMT coverage suggests the need to raise clinical awareness and increase the FMT activity in Europe by at least 10-fold to meet the true, indicated need. (C) 2021 The Authors. Published by Elsevier Ltd.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet regional health - Europe
ISSN
2666-7762
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
October
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
"art. no. 100181"
UT code for WoS article
000709710400016
EID of the result in the Scopus database
2-s2.0-85111661064